Please login to the form below

Not currently logged in
Email:
Password:

Intercept Pharma

This page shows the latest Intercept Pharma news and features for those working in and with pharma, biotech and healthcare.

Intercept hit hard as FDA issues Ocaliva safety notice

Intercept hit hard as FDA issues Ocaliva safety notice

Intercept Pharma has only had a few months to revel in its first product launch before a safety warning from the FDA knocked it back. ... Intercept claimed an accelerated FDA approval for Ocaliva in May 2016 and followed that with an EMA green light in

Latest news

  • Intercept gets EU nod for rare liver disease therapy Intercept gets EU nod for rare liver disease therapy

    Intercept gets EU nod for rare liver disease therapy. Ocaliva approved as a combination treatment for primary biliary cholangitis. ... Intercept Pharma now has approval for its Ocaliva drug for primary biliary cholangitis (PBC) therapy Ocaliva on both

  • Allergan buys two NASH drug developers in one day Allergan buys two NASH drug developers in one day

    pipeline. The acquisition puts Allergan in a race to market with other FXR-targeting drugs for NASH, including Intercept Pharma which has a drug with mechanism already on the market for ... Allergan maintains AKN-083 is potentially best-in-class.

  • FDA panel backs Intercept's rare liver disease drug FDA panel backs Intercept's rare liver disease drug

    Intercept Pharma has secured a positive FDA advisory committee vote for its rare liver disease therapy Ocaliva, considered by some to be a blockbuster-in-waiting. ... Intercept owns worldwide rights to Ocaliva outside Japan and China, where it has

More from news
Approximately 3 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

The Holy Grail of HCP Access
This is the data you need to gain access....
No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....

Infographics